F
Francis Kajumo
Researcher at Albert Einstein College of Medicine
Publications - 15
Citations - 2715
Francis Kajumo is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Viral entry & Coreceptor activity. The author has an hindex of 14, co-authored 15 publications receiving 2650 citations. Previous affiliations of Francis Kajumo include Aaron Diamond AIDS Research Center.
Papers
More filters
Journal ArticleDOI
A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure
James M. Binley,Rogier W. Sanders,Brian Clas,Norbert Schuelke,Aditi Master,Yong Guo,Francis Kajumo,Deborah J. Anselma,Paul J. Maddon,William C. Olson,John P. Moore +10 more
TL;DR: A disulfide bond is introduced between the C-terminal region of gp120 and the immunodominant segment of the gp41 ectodomain, producing a properly folded envelope glycoprotein complex which has antigenic properties which resemble those of the virion-associated complex.
Journal ArticleDOI
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
Tatjana Dragic,Alexandra Trkola,Daniah A. D. Thompson,Emmanuel Cormier,Francis Kajumo,Elizabeth S. Maxwell,Steven Lin,Weiwen Ying,Steven O. Smith,Thomas P. Sakmar,John P. Moore +10 more
TL;DR: HIV-1 entry into CD4(+) cells requires the sequential interactions of the viral envelope glycoproteins with CD4 and a coreceptor such as the chemokine receptors CCR5 and CXCR4 to be blocked, and the TAK-779 molecule is explored.
Journal ArticleDOI
CD81 is an entry coreceptor for hepatitis C virus.
TL;DR: Results indicate that CD81 functions as a post-attachment entry coreceptor and that other cellular factors act in concert with CD81 to mediate HCV binding and entry into hepatocytes.
Journal ArticleDOI
Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5
William C. Olson,Gwénaël Rabut,Kirsten A. Nagashima,Diep N. H. Tran,Deborah J. Anselma,Simon Monard,Jeremy P. Segal,Daniah A. D. Thompson,Francis Kajumo,Yong Guo,John P. Moore,Paul J. Maddon,Tatjana Dragic +12 more
TL;DR: Surprisingly, there was no correlation between the ability of a MAb to inhibit HIV-1 fusion-entry and its ability to inhibit either the binding of a gp120-soluble CD4 complex to CCR5 or CC-chemokine activity.
Journal ArticleDOI
Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry
Tatjana Dragic,Alexandra Trkola,Steven Lin,Kirsten A. Nagashima,Francis Kajumo,Lu Zhao,William C. Olson,Lijun Wu,Charles R. Mackay,Graham P. Allaway,Thomas P. Sakmar,John P. Moore,Paul J. Maddon +12 more
TL;DR: It is shown that substitutions of the negatively charged aspartic acid residues at positions 2 and 11 and a glutamic acid residue at position 18 (E18A), individually or in combination, impair or abolish CCR5-mediated HIV-1 entry for the ADA and JR-FL M-tropic strains and the DH123 dual- Tropic strain.